Thiopurine methyltransferase activity and adverse effects of azathioprine in at risk paediatric inflammatory bowel disease patients

被引：0
|
作者：
Parry, Christopher [1 ]
Hawcutt, Daniel [1 ]
Krishnamurthy, Srividyadhari [1 ]
Renji, Elizabeth [1 ]
机构：
[1] Alder Hey Childrens Hosp, Liverpool, Merseyside, England
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2021年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OC034
引用
收藏
页码：1622 / 1622
页数：1
相关论文
共 50 条
  • [21] Thiopurine methyltransferase activity is correlated with azathioprine metabolite levels in inflammatory bowel disease patients in clinical gastroenterology practice
    Bloomfeld, RS
    Bickston, SJ
    Levine, ME
    Carroll, SM
    Smith, K
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10): : S255 - S255
  • [22] Thiopurine metabolites and the role of thiopurine methyltransferase activity in inflammatory bowel disease
    Qasim, A
    Buckley, M
    O' Morain, CA
    GUT, 2002, 51 (01) : 141 - 141
  • [23] Efficacy, tolerance of azathioprine and pharmacogenetics of thiopurine methyltransferase in pediatric inflammatory bowel disease
    Zhang, D.
    Languepin, J.
    Medard, Y.
    Cezard, J. P.
    Jacqz-Aigrain, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 38 - 38
  • [24] Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease
    Stocco, G.
    Martelossi, S.
    Decorti, G.
    Bartoli, F.
    Ventura, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (07) : 1083 - 1084
  • [25] The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases
    Hlavaty, T.
    Batovsky, M.
    Balakova, D.
    Pav, I
    Celec, P.
    Gregus, M.
    Zakuciova, M.
    Hlista, M.
    Horakova, M.
    Desatova, B.
    Koller, T.
    Toth, J.
    Kadasi, L.
    Huorka, M.
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2013, 114 (04): : 199 - 205
  • [26] Adverse effects of azathioprine in patients with inflammatory bowel disease (IBD)
    Ramirez de la Piscina, P.
    Estrada, S.
    Duca, I.
    Spicakova, K.
    Ganchegui, I.
    Calderon, M. D. R.
    Campos, A.
    Salvador, M.
    Delgado, E.
    Lopez Barbarin, J. M.
    Garcia Campos, F.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S309 - S309
  • [27] Thiopurine Methyltransferase and Inosine Triphosphate Pyrophosphohydrolase Genotypes Among Patients With Inflammatory Bowel Disease Treated With Azathioprine
    Aljudaibi, Bandar
    Gregor, James C.
    Chande, Nilesh
    Kim, Richard B.
    Ponich, Terry P.
    Schwarz, Ute I.
    GASTROENTEROLOGY, 2011, 140 (05) : S294 - S294
  • [28] Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease
    Winter, J. W.
    Gaffney, D.
    Shapiro, D.
    Spooner, R. J.
    Marinaki, A. M.
    Sanderson, J. D.
    Mills, P. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (09) : 1069 - 1077
  • [29] Relationship of thiopurine methyltransferase (TPMT) activity to mean corpuscular volume (MCV) in inflammatory bowel disease (IBD) patients maintained on azathioprine
    Joy, D
    MacPherson, R
    Campbell, S
    Kingstone, K
    Ghosh, S
    GUT, 2002, 50 : A79 - A79
  • [30] Clinical implications of thiopurine-methyltransferase activity (TPMTe) induction of azathioprine (AZA) treatment in patients with inflammatory bowel disease (IBD)
    Domenech, E
    Garcia-Planella, E
    Fluvia, L
    Bernal, I
    Cabre, E
    Gassull, M
    GASTROENTEROLOGY, 2003, 124 (04) : A195 - A195
12345